Cargando…

Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020

Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Cheng, Leung, Nancy Hiu Lan, Cheng, Yating, Lei, Hui, Ling, Shiman, Lin, Xia, Tao, Ran, Huang, Xianzhong, Guan, Wenda, Yang, Zifeng, Cowling, Benjamin John, Zanin, Mark, Wong, Sook-San
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619097/
https://www.ncbi.nlm.nih.gov/pubmed/34832661
http://dx.doi.org/10.3390/pathogens10111505
_version_ 1784604907494440960
author Xiao, Cheng
Leung, Nancy Hiu Lan
Cheng, Yating
Lei, Hui
Ling, Shiman
Lin, Xia
Tao, Ran
Huang, Xianzhong
Guan, Wenda
Yang, Zifeng
Cowling, Benjamin John
Zanin, Mark
Wong, Sook-San
author_facet Xiao, Cheng
Leung, Nancy Hiu Lan
Cheng, Yating
Lei, Hui
Ling, Shiman
Lin, Xia
Tao, Ran
Huang, Xianzhong
Guan, Wenda
Yang, Zifeng
Cowling, Benjamin John
Zanin, Mark
Wong, Sook-San
author_sort Xiao, Cheng
collection PubMed
description Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.
format Online
Article
Text
id pubmed-8619097
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86190972021-11-27 Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020 Xiao, Cheng Leung, Nancy Hiu Lan Cheng, Yating Lei, Hui Ling, Shiman Lin, Xia Tao, Ran Huang, Xianzhong Guan, Wenda Yang, Zifeng Cowling, Benjamin John Zanin, Mark Wong, Sook-San Pathogens Article Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06–0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01–0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03–0.79%) in persons aged 10–19, 0.16% (95% CI: 0.07–0.33%) in persons aged 20–39, 0.13% (95% CI: 0.03–0.33%) in persons aged 40–59 and 0.18% (95% CI: 0.07–0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2. MDPI 2021-11-18 /pmc/articles/PMC8619097/ /pubmed/34832661 http://dx.doi.org/10.3390/pathogens10111505 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xiao, Cheng
Leung, Nancy Hiu Lan
Cheng, Yating
Lei, Hui
Ling, Shiman
Lin, Xia
Tao, Ran
Huang, Xianzhong
Guan, Wenda
Yang, Zifeng
Cowling, Benjamin John
Zanin, Mark
Wong, Sook-San
Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_full Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_fullStr Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_full_unstemmed Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_short Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
title_sort seroprevalence of antibodies to sars-cov-2 in guangdong province, china between march to june 2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619097/
https://www.ncbi.nlm.nih.gov/pubmed/34832661
http://dx.doi.org/10.3390/pathogens10111505
work_keys_str_mv AT xiaocheng seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT leungnancyhiulan seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT chengyating seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT leihui seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT lingshiman seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT linxia seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT taoran seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT huangxianzhong seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT guanwenda seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT yangzifeng seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT cowlingbenjaminjohn seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT zaninmark seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020
AT wongsooksan seroprevalenceofantibodiestosarscov2inguangdongprovincechinabetweenmarchtojune2020